View Older Stories View More Recent Stories

Jun 16, 2021 03:50PM FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
Jun 4, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 25, 2021 08:00AM Blueprint Medicines to Present at Upcoming Investor Conferences
May 19, 2021 05:00PM Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Ad
May 17, 2021 08:00AM Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
May 5, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 29, 2021 07:00AM Blueprint Medicines Reports First Quarter 2021 Financial Results
Apr 22, 2021 08:00AM Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
Apr 11, 2021 02:00PM Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021
Apr 10, 2021 08:30AM Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021
Apr 7, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 5, 2021 08:00AM Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
Mar 25, 2021 07:09AM IMV Inc. (IMV) Names Kyle Kuvalanka to Board
Mar 25, 2021 07:05AM IMV Appoints Kyle Kuvalanka to Board of Directors
Mar 10, 2021 04:30PM Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021
Mar 5, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 3, 2021 08:00AM Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Feb 17, 2021 07:00AM Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 10, 2021 08:00AM Blueprint Medicines to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 17, 2021
Feb 5, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 11, 2021 08:18AM Blueprint Medicines (BPMC) Reports Portfolio Milestones and Outlines 2021 Roadmap
Jan 11, 2021 08:05AM Blueprint Medicines Announces R&D Leadership Transitions
Jan 11, 2021 08:00AM Blueprint Medicines Reports Portfolio Milestones and Outlines 2021 Roadmap for Precision Medicine Leadership
Jan 5, 2021 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 17, 2020 08:03AM Blueprint Medicines (BPMC) Submits sNDA to FDA for AYVAKIT for Treatment of Advanced Systemic Mastocytosis
Dec 17, 2020 08:00AM Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Dec 7, 2020 08:00AM Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis
Dec 4, 2020 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 1, 2020 03:16PM Blueprint Medicines (BPMC) Announces FDA Approval of GAVRETO for Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
Dec 1, 2020 03:15PM Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
Nov 23, 2020 08:00AM Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition
Nov 3, 2020 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 29, 2020 07:00AM Blueprint Medicines Reports Third Quarter 2020 Financial Results
Oct 22, 2020 08:00AM Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
Oct 2, 2020 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 25, 2020 11:48AM Blueprint Medicines (BPMC) Announces EC Approval of AYVAKYT for Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Sep 25, 2020 11:46AM Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Sep 22, 2020 07:07AM Blueprint Medicines (BPMC) Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT in Patients with Advanced SM
Sep 22, 2020 07:00AM Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis
Sep 20, 2020 08:25AM Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO™ (Pralsetinib) in Patients with Advanced RET-Mutant Medullary Thyroid Ca
Sep 17, 2020 08:09AM Blueprint Medicines (BPMC) Highlights Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer
Sep 17, 2020 08:00AM Blueprint Medicines Presents Foundational Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity in Treatment-Resistant EGFR-Mutated Lung Cancer at ESMO Virtual Congress 2020
Sep 9, 2020 04:01PM Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference
Sep 8, 2020 08:04AM Blueprint Medicines (BPMC) Announces FDA Approval of GAVRETO
Sep 4, 2020 07:00PM Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Sep 4, 2020 08:00AM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 1, 2020 08:00AM Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
Aug 4, 2020 08:00AM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 30, 2020 07:00AM Blueprint Medicines Reports Second Quarter 2020 Financial Results
Jul 24, 2020 08:35AM Blueprint Medicines (BPMC) Granted Positive CHMP Opinion for Avapritinib for Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
View More Recent Stories View Older Stories